Robert W. Baird Sticks to Their Buy Rating for Diplomat Pharmacy

By Carrie Williams

In a report issued on September 13, Eric Coldwell from Robert W. Baird reiterated a Buy rating on Diplomat Pharmacy (NYSE: DPLO), with a price target of $20. The company’s shares closed on Friday at $19.68.

According to, Coldwell is a 4-star analyst with an average return of 7.2% and a 55.2% success rate. Coldwell covers the Services sector, focusing on stocks such as AmerisourceBergen Corporation, Walgreens Boots Alliance, and Quintiles Transnational.

Currently, the analyst consensus on Diplomat Pharmacy is Moderate Buy and the average price target is $18.92, representing a -3.9% downside.

In a report issued on September 12, Needham also reiterated a Buy rating on the stock with a $19.75 price target.

The company has a one year high of $31.33 and a one year low of $12.25. Currently, Diplomat Pharmacy has an average volume of 658.7K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Diplomat Pharmacy, Inc. operates as an independent specialty pharmacy in the United States. The firm stocks, dispenses, and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. It focuses on improving the lives of patients with complex chronic diseases.